AKT1 and glioblastoma: Given the limited success of EGFR tyrosine kinase inhibitors in some GBM patients, MK2206 represents a promising targeted therapy by addressing the underlying AKT-driven epigenetic changes and cytoskeletal remodeling associated with GBM invasiveness [90].